ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
Comparative randomised, open-label, parallel-group trial (n≈403) of ECT (3×/week, up to 9 sessions) versus ketamine infusion (0.5 mg/kg IV, 2×/week, up to 6 sessions) for treatment-resistant depression with patient-reported outcomes as primary measures.
Details
Randomised, open-label, parallel-group study comparing ECT given three times per week (up to nine treatments) with intravenous ketamine given twice per week (initial 0.5 mg/kg over 40 minutes, up to six treatments) in adults with treatment-resistant major depressive episode.
Primary outcomes are patient-reported symptom measures collected during an acute treatment phase of three to five weeks; responders may be followed for up to six months. Eligibility requires MADRS >20 and prior inadequate response to ≥2 antidepressant trials.